Senators reach tentative deal on $10 billion in additional Covid funding, Romney says

Senators reach tentative deal on  billion in additional Covid funding, Romney says


U.S. Senator Mitt Romney (R-UT) walks through the Senate Subway on his way to a security briefing for senators on Russia’s invasion of Ukraine, on Capitol Hill in Washington, March 30, 2022.

Elizabeth Frantz | Reuters

Senate Republicans and Democrats have reached a tentative deal on $10 billion in additional Covid funding, less than half the sum that President Joe Biden had requested to shore up the nation’s pandemic response ahead of another potential infection wave.

Sen. Mitt Romney, R-Utah, told reporters he had a deal with Senate Majority Leader Chuck Schumer, D-NY, to cover the spending by redirecting money from the American Rescue Plan passed last year. The funding is far less than $22.5 billion the White House had requested from Congress.

Biden warned yesterday that the U.S. would not have enough Covid vaccine doses for all Americans this fall if Congress failed to act. The White House has also warned the uninsured would no longer have coverage for Covid testing, treatments and vaccinations. The U.S. would also face shortages of monoclonal antibody treatments, antiviral pills and Covid testing, according to administration officials.

It is not clear what the package would cover, as senators have not yet released details. The text of the agreement, when finished, would go the Congressional Budget Office to show that the funding is balanced by offsets.

House Democrats originally sought to pass $15 billion in Covid money earlier this month as part of a larger government funding package. However, House Speaker Nancy Pelosi pulled the Covid funding after Republicans and Democrats failed to agree on how to pay for it.

The GOP insisted on covering any new spending by clawing back money already appropriated for state and local governments, but Democrats rejected that demand.

A more contagious variant of omicron, BA.2, is spreading in the U.S. It now makes more than half of all infections that have undergone genetic sequencing, according to the Centers for Disease Control and Prevention. BA.2 has caused new Covid outbreaks in Europe and China, raising concerns the subvariant could do the same in the U.S.

White House chief medical advisor Dr. Anthony Fauci said earlier this month that BA.2 will likely cause an increase of infections in the U.S., though he doesn’t expect another surge. Epidemiologists say the U.S. could face another wave in the fall, as immunity from the vaccines wanes and people move indoors due to the colder weather.

CNBC Health & Science

Read CNBC’s latest global coverage of the Covid pandemic:



Source

Abortion pill makers brace for restrictions a year after Trump’s election
Health

Abortion pill makers brace for restrictions a year after Trump’s election

Mifepristone and Misoprostol pills are pictured Wednesday, Oct. 3, 2018, in Skokie, Illinois. Erin Hooley | Chicago Tribune | Tribune News Service | Getty Images Just over a year since Donald Trump was elected president again, the $6.9 billion abortion pill industry is operating under the same federal rules he inherited from former President Joe […]

Read More
Republicans push Obamacare tax credit alternatives as enrollment deadline looms
Health

Republicans push Obamacare tax credit alternatives as enrollment deadline looms

An Obamacare sign is displayed outside an insurance agency on Nov. 12, 2025 in Miami, Florida. Joe Raedle | Getty Images With enhanced Obamacare tax credits set to expire at the end of the year, Republicans are proposing new alternatives aimed at lowering the cost of health care. Their window for doing so is rapidly […]

Read More
Novo Nordisk shares plunge 10% after Alzheimer’s drug trial fails to hit key target
Health

Novo Nordisk shares plunge 10% after Alzheimer’s drug trial fails to hit key target

The Novo Nordisk A/S headquarters in Bagsvaerd, Denmark, on Wednesday, Nov. 5, 2025. Nichlas Pollier | Bloomberg | Getty Images Shares of Novo Nordisk on Monday fell as much 11% after the Danish drug pharmaceutical company said a highly-anticipated trial for Alzheimer’s disease failed to meet its main goal. The trial tested whether semaglutide — the […]

Read More